JP2019534858A - Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤 - Google Patents

Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤 Download PDF

Info

Publication number
JP2019534858A
JP2019534858A JP2019513444A JP2019513444A JP2019534858A JP 2019534858 A JP2019534858 A JP 2019534858A JP 2019513444 A JP2019513444 A JP 2019513444A JP 2019513444 A JP2019513444 A JP 2019513444A JP 2019534858 A JP2019534858 A JP 2019534858A
Authority
JP
Japan
Prior art keywords
crd
ligand
peptide
cancer
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534858A5 (OSRAM
Inventor
アーロン ヒュー ナイル，
アーロン ヒュー ナイル，
インナン チャン，
インナン チャン，
リーチュアン チョウ，
リーチュアン チョウ，
ラミ ハヌーシュ，
ラミ ハヌーシュ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2019534858A publication Critical patent/JP2019534858A/ja
Publication of JP2019534858A5 publication Critical patent/JP2019534858A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019513444A 2016-09-09 2017-09-08 Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤 Pending JP2019534858A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662385848P 2016-09-09 2016-09-09
US62/385,848 2016-09-09
US201662419331P 2016-11-08 2016-11-08
US62/419,331 2016-11-08
PCT/US2017/050841 WO2018049275A1 (en) 2016-09-09 2017-09-08 Selective peptide inhibitors of frizzled

Publications (2)

Publication Number Publication Date
JP2019534858A true JP2019534858A (ja) 2019-12-05
JP2019534858A5 JP2019534858A5 (OSRAM) 2020-10-22

Family

ID=60022161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513444A Pending JP2019534858A (ja) 2016-09-09 2017-09-08 Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤

Country Status (5)

Country Link
US (1) US20190359653A1 (OSRAM)
EP (1) EP3509616A1 (OSRAM)
JP (1) JP2019534858A (OSRAM)
CN (1) CN110198729A (OSRAM)
WO (1) WO2018049275A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100520A1 (ja) * 2023-11-10 2025-05-15 ペプチドリーム株式会社 ペプチド、ペプチド複合体、医薬組成物、細胞培養用組成物、及び医療用、診断用又は研究用に用いられる組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102664A1 (en) * 2018-11-16 2020-05-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Biomarkers and treatment of neuronal injury and neurodegeneration
CN112210011A (zh) * 2019-11-06 2021-01-12 上海健康医学院 一种靶向Frizzled7人源化抗体及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503990A (ja) * 2008-09-26 2012-02-16 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
JP2013530929A (ja) * 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
WO2015023851A1 (en) * 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
EP2975047A1 (en) * 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546807C2 (OSRAM) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
EP0760012A4 (en) 1994-06-10 1997-07-02 Symbiotech Inc METHODS FOR DETECTING COMPOUNDS BY MEANS OF GENETICALLY MODIFIED LAMBDA BACTERIOPHAGE
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JPH11507246A (ja) 1996-03-20 1999-06-29 ダイアックス コープ． 巨大分子用アフィニティ・リガンドの設計
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
ATE279203T1 (de) 1996-06-10 2004-10-15 Scripps Research Inst Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
EP0929361A4 (en) 1996-10-04 2000-07-19 Whatman Inc DEVICE AND METHOD FOR SIMULTANEOUS MULTIPLE SYNTHESIS
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
WO1998020036A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
WO2006036175A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503990A (ja) * 2008-09-26 2012-02-16 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
JP2013530929A (ja) * 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
WO2015023851A1 (en) * 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
EP2975047A1 (en) * 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, vol. 4, JPN7021002731, 1 December 2012 (2012-12-01), pages 007880 - 1, ISSN: 0004727104 *
SCIENCE, vol. 337, no. 6090, JPN6021027851, 31 May 2012 (2012-05-31), pages 44 - 45, ISSN: 0004727103 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100520A1 (ja) * 2023-11-10 2025-05-15 ペプチドリーム株式会社 ペプチド、ペプチド複合体、医薬組成物、細胞培養用組成物、及び医療用、診断用又は研究用に用いられる組成物

Also Published As

Publication number Publication date
US20190359653A1 (en) 2019-11-28
WO2018049275A1 (en) 2018-03-15
CN110198729A (zh) 2019-09-03
EP3509616A1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
JP7602514B2 (ja) シスチンノットスキャフォールドプラットフォーム
CN114945584A (zh) 重组肽-mhc复合物结合蛋白及其生成和用途
US20190359653A1 (en) Selective peptide inhibitors of frizzled
CN117756909A (zh) 改进的抗衰老化合物及其在癌症治疗中的用途
HK40013986A (zh) 卷曲蛋白的选择性肽抑制剂
JP2017526379A (ja) シャガシンに基づく足場組成物、方法及び使用
US20250099534A1 (en) Ubiquitin high affinity cyclic peptides and methods of use thereof
WO2020089912A1 (en) Anti-biofilm compositions
HK40072594A (en) Cystine knot scaffold platform
HK40120567A (zh) 胱氨酸结支架平台
Eddinger Diverse Design Strategies for the Development of Peptide Inhibitors of Protein-Protein Interactions
HK40067003A (en) Cystine knot scaffold platform
HK40067003B (zh) 胱氨酸结支架平台
HK1253318B (zh) 胱氨酸结支架平台

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315